Opinion

Video

Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC

Author(s):

Joyce A. O'Shaughnessy, MDMelinda L. Telli, MD

The panel provides comprehensive insights on approaching first-line treatment of patients with HER2+ metastatic breast cancer and the role of neratinib.

Video content above is prompted by the following question:

  • What are the standard-of-care regimens for first-line treatment of HER2+ metastatic breast cancer (mBC)?
Related Videos
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
Sara M. Tolaney, MD, MPH
Dana M. Chase, MD, associate professor, obstetrics and gynecology, Division of Gynecologic Oncology, the University of California, Los Angeles
Sara M. Tolaney, MD, MPH
5 KOLs are featured in this series.
5 KOLs are featured in this series.
A panel of 5 experts on CLL
Related Content
The OncFive: Top Oncology Articles for the Week of 8/25
August 31st 2024

The OncFive: Top Oncology Articles for the Week of 8/25

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

State of the Science Summit - Breast Cancer: Chaired by Christos Vaklavas, MD
August 29th 2024

State of the Science Summit - Breast Cancer: Chaired by Christos Vaklavas, MD

Anne Chiang, MD, PhD, associate professor, medicine, Section of Medical Oncology, Yale School of Medicine; associate director, Clinical Initiatives, Yale Cancer Center
August 29th 2024

Chiang Contextualizes the Optimal Use of Lurbinectedin in SCLC Management

State of the Science Summit - Genitourinary Cancers: Chaired by Adam E. Singer, MD, PhD
August 27th 2024

State of the Science Summit - Genitourinary Cancers: Chaired by Adam E. Singer, MD, PhD

Jason A. Mouabbi, MD, of MD Anderson Cancer Center
August 26th 2024

DESTINY-Breast06 Redefines Treatment Paradigms, Calls Necessity of HER2 Testing for T-DXd into Question in HR+ Breast Cancer